The Senate Committee on Commerce, Science, and Transportation has approved the Pharmacy Benefit Manager Transparency Act (S.1339). The bill now heads to the full Senate for a vote.
The bill aims to stop deceptive and anticompetitive pricing schemes by pharmacy benefit managers (PBMs). Currently, three PBMs control 80% of the prescription drug market, and these intermediaries in the drug supply pricing chain operate with little or no regulation by the government. The practices by PBMs increase the prices of prescription drugs for consumers and restrict the drugs that health plans cover.
The bill includes the following provisions:
- Eliminating “spread pricing,” in which PBMs charge health plans and payers more for drugs than what they reimburse pharmacies;
- Prohibiting PBMs from clawing back payments to pharmacies, increasing fees, or lowering reimbursements to offset reimbursement charges in federally funded health plans; and
- Requiring PBMs to pass on all rebates to the plan or payer and fully disclose the cost and reimbursement of drugs to the plan.